These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 16586011)

  • 1. A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane.
    Ajani JA; Safran H; Bokemeyer C; Shah MA; Lenz HJ; Van Cutsem E; Burris HA; Lebwohl D; Mullaney B
    Invest New Drugs; 2006 Sep; 24(5):441-6. PubMed ID: 16586011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.
    Bunnell C; Vahdat L; Schwartzberg L; Gralow J; Klimovsky J; Poulart V; Peck R; Thomas E
    Clin Breast Cancer; 2008 Jun; 8(3):234-41. PubMed ID: 18650153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study.
    Burtness BA; Manola J; Axelrod R; Argiris A; Forastiere AA;
    Ann Oncol; 2008 May; 19(5):977-83. PubMed ID: 18296423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of ixabepilone in taxane-resistant patients with metastatic breast cancer previously treated with anthracyclines: results of a phase II study in Japan.
    Aogi K; Rai Y; Ito Y; Masuda N; Watanabe J; Horiguchi J; Tokudome T; Takashima S
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1427-33. PubMed ID: 23536163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.
    Thomas E; Tabernero J; Fornier M; Conté P; Fumoleau P; Lluch A; Vahdat LT; Bunnell CA; Burris HA; Viens P; Baselga J; Rivera E; Guarneri V; Poulart V; Klimovsky J; Lebwohl D; Martin M
    J Clin Oncol; 2007 Aug; 25(23):3399-406. PubMed ID: 17606975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group.
    Liu G; Chen YH; Dipaola R; Carducci M; Wilding G
    Clin Genitourin Cancer; 2012 Jun; 10(2):99-105. PubMed ID: 22386239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
    Steinberg M
    Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients.
    Smith JW; Vukelja S; Rabe A; Wentworth-Hartung N; Koutrelakos N; Shao SH; Whittaker T; Wang Y; Asmar L; McDowell DO; Mukhopadhyay P; O'Shaughnessy J
    Breast Cancer Res Treat; 2013 Nov; 142(2):381-8. PubMed ID: 24166282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study.
    De Geest K; Blessing JA; Morris RT; Yamada SD; Monk BJ; Zweizig SL; Matei D; Muller CY; Richards WE
    J Clin Oncol; 2010 Jan; 28(1):149-53. PubMed ID: 19917861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer.
    Low JA; Wedam SB; Lee JJ; Berman AW; Brufsky A; Yang SX; Poruchynsky MS; Steinberg SM; Mannan N; Fojo T; Swain SM
    J Clin Oncol; 2005 Apr; 23(12):2726-34. PubMed ID: 15837987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II Clinical Trial of Ixabepilone in Metastatic Cervical Carcinoma.
    Burotto M; Edgerly M; Poruchynsky M; Velarde M; Wilkerson J; Kotz H; Bates S; Balasubramaniam S; Fojo T
    Oncologist; 2015 Jul; 20(7):725-6. PubMed ID: 26040622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase II Multi-Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma.
    Burotto M; Edgerly M; Velarde M; Balasubramaniam S; Drabkin H; Gormaz JG; O'Sullivan C; Madan R; Fojo T
    Oncologist; 2017 Aug; 22(8):888-e84. PubMed ID: 28679644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes.
    Denduluri N; Low JA; Lee JJ; Berman AW; Walshe JM; Vatas U; Chow CK; Steinberg SM; Yang SX; Swain SM
    J Clin Oncol; 2007 Aug; 25(23):3421-7. PubMed ID: 17606971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.
    Aghajanian C; Burris HA; Jones S; Spriggs DR; Cohen MB; Peck R; Sabbatini P; Hensley ML; Greco FA; Dupont J; O'Connor OA
    J Clin Oncol; 2007 Mar; 25(9):1082-8. PubMed ID: 17261851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
    Hussain M; Tangen CM; Lara PN; Vaishampayan UN; Petrylak DP; Colevas AD; Sakr WA; Crawford ED;
    J Clin Oncol; 2005 Dec; 23(34):8724-9. PubMed ID: 16314632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
    Thomas ES; Gomez HL; Li RK; Chung HC; Fein LE; Chan VF; Jassem J; Pivot XB; Klimovsky JV; de Mendoza FH; Xu B; Campone M; Lerzo GL; Peck RA; Mukhopadhyay P; Vahdat LT; Roché HH
    J Clin Oncol; 2007 Nov; 25(33):5210-7. PubMed ID: 17968020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer.
    Denduluri N; Lee JJ; Walshe J; Berman AW; Vatas U; Chow CK; Steinberg SM; Cox MC; Low JA; Swain SM
    Invest New Drugs; 2007 Feb; 25(1):63-7. PubMed ID: 16933153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy.
    Kim YH; Muro K; Yasui H; Chen JS; Ryu MH; Park SH; Chu KM; Choo SP; Sanchez T; DelaCruz C; Mukhopadhyay P; Lainas I; Li CP
    Cancer Chemother Pharmacol; 2012 Oct; 70(4):583-90. PubMed ID: 22886073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortium.
    Okuno S; Maples WJ; Mahoney MR; Fitch T; Stewart J; Fracasso PM; Kraut M; Ettinger DS; Dawkins F; Erlichman C
    J Clin Oncol; 2005 May; 23(13):3069-73. PubMed ID: 15860865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.
    Galsky MD; Small EJ; Oh WK; Chen I; Smith DC; Colevas AD; Martone L; Curley T; Delacruz A; Scher HI; Kelly WK
    J Clin Oncol; 2005 Mar; 23(7):1439-46. PubMed ID: 15735119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.